Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $73,468 | $70,008 | $62,465 | $59,867 |
| % Growth | 4.9% | 12.1% | 4.3% | – |
| Cost of Goods Sold | $8,504 | $7,115 | $8,574 | $5,552 |
| Gross Profit | $64,964 | $62,893 | $53,891 | $54,315 |
| % Margin | 88.4% | 89.8% | 86.3% | 90.7% |
| R&D Expenses | $8,435 | $7,432 | $5,743 | $8,107 |
| G&A Expenses | $0 | $25,170 | $19,369 | $31,163 |
| SG&A Expenses | $26,182 | $26,018 | $20,339 | $45,257 |
| Sales & Mktg Exp. | $0 | $848 | $970 | $14,094 |
| Other Operating Expenses | $602 | $9,360 | $5,962 | $2,620 |
| Operating Expenses | $35,219 | $42,810 | $32,044 | $55,984 |
| Operating Income | $29,745 | $20,083 | $21,847 | -$1,669 |
| % Margin | 40.5% | 28.7% | 35% | -2.8% |
| Other Income/Exp. Net | $2,217 | $2,073 | $2,502 | $2,842 |
| Pre-Tax Income | $31,962 | $22,156 | $24,349 | $1,173 |
| Tax Expense | $411 | $643 | $1,005 | -$256 |
| Net Income | $31,551 | $21,513 | $23,344 | $1,429 |
| % Margin | 42.9% | 30.7% | 37.4% | 2.4% |
| EPS | 0.24 | 0.16 | 0.16 | 0.01 |
| % Growth | 50% | 0% | 1,500% | – |
| EPS Diluted | 0.23 | 0.15 | 0.16 | 0.01 |
| Weighted Avg Shares Out | 137,178 | 138,917 | 138,917 | 142,179 |
| Weighted Avg Shares Out Dil | 136,008 | 143,199 | 138,917 | 147,675 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,217 | $3,190 | $3,569 | $3,988 |
| Interest Expense | $0 | $1,117 | $1,067 | $1,146 |
| Depreciation & Amortization | $4,865 | $4,864 | $4,856 | $4,862 |
| EBITDA | $36,827 | $28,137 | $30,272 | $7,181 |
| % Margin | 50.1% | 40.2% | 48.5% | 12% |